List view / Grid view
8 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from a cohort of patients in its ongoing Phase 1b trial (CheckMate -039) which evaluated PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in patients with relapsed or refractory hematological malignancies (n=23)...
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
8 December 2014 | By Astellas
Astellas Pharma Europe Ltd. announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for enzalutamide (trade name XTANDI™)...
CAMO Software announced the launch of Service Pack 2014 for their all-in-one Multivariate Data Analysis (MVA) and Design of Experiments (DoE) software, The Unscrambler® X...
5 December 2014 | By Pierre Fabre
This award is recognition of both Pierre Fabre's expertise in dermatology, one of its development priorities, and of its ability to form public-private partnerships, such as that established with the University of Bordeaux...
5 December 2014 | By Abbott
Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition...
5 December 2014 | By Evgen Pharma
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its intention to join the AIM market of the London Stock Exchange by way of a Placing to raise up to £20 million...
4 December 2014 | By Deloitte
In a written ministerial statement issued, the Financial Secretary to the Treasury, Mr David Gauke, confirmed that the Organisation for Economic Cooperation and Development (OECD) has adopted all of the proposals...
Phase I study evaluating safety and tolerability of VXM01 in pancreatic cancer...
4 December 2014 | By GlobalData
The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.
4 December 2014 | By Santen
Following the launch of Santen in Italy in October 2014, Santen Italy s.r.l (Milano, Italy) (Santen) announces that Paolo Casati has been named General Manager of Santen Italy, effective November 21st, 2014...
4 December 2014 | By Bioquell
Norovirus season is upon us and Bioquell has issued tools to help combat the spread...
4 December 2014 | By Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations...
3 December 2014 | By Sagentia
Sagentia, a global science, product and technology development company, announced today that it is working with Chrono Therapeutics on the development of SmartStop™, the world’s first programmable and wearable nicotine delivery device to help people quit smoking...
3 December 2014 | By GlobalData
The Age-related Macular Degeneration treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm GlobalData.
